Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Licenses OTC Nexium Rights From AstraZeneca

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer will make an upfront payment of $250 million for global rights to market a potential 20 mg OTC version of proton pump inhibitor Nexium, currently available only by prescription. Filing of Rx-to-OTC switch application expected in first half of 2013.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel